Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects
Although thyroid hormone (TH) has anti-obesity potential, systemic administration of TH causes severe adverse effects without obvious weight loss. Here, the authors show that adipose tissue-targeted delivery of TH with liposomes is a safe and efficient strategy to treat obesity and its related compl...
Main Authors: | Kang Chen, Lai Yee Cheong, Yuan Gao, Yaming Zhang, Tianshi Feng, Qin Wang, Leigang Jin, Eric Honoré, Karen S. L. Lam, Weiping Wang, Xiaoyan Hui, Aimin Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-35470-4 |
Similar Items
-
Metabolic Systemic Effects Triiodothyronine
by: E. A. Troshina, et al.
Published: (2020-07-01) -
Triiodothyronine Acts as a Smart Influencer on Hsp90 via a Triiodothyronine Binding Site
by: Lu Fan, et al.
Published: (2022-06-01) -
The correlation between triiodothyronine and the severity of liver fibrosis
by: Weiwei He, et al.
Published: (2022-12-01) -
Free Triiodothyronine and Free Triiodothyronine to Free Thyroxine Ratio Predict All-Cause Mortality in Patients with Diabetic Foot Ulcers
by: Hong J, et al.
Published: (2022-02-01) -
OBESITY AND PERIVASCULAR ADIPOSITY IN ATHEROSCLEROSIS
by: Kylintireas, I, et al.
Published: (2011)